Literature DB >> 24153222

Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?

Susie H Park1, Robin C Wackernah, Glen L Stimmel.   

Abstract

BACKGROUND: There is a warning associated with all serotonergic antidepressants and its concomitant use with tramadol due to the concern for a drug-drug interaction resulting in serotonin syndrome (SS). The prescribing of antidepressants with tramadol may be unnecessarily restricted due to fear of causing this syndrome.
OBJECTIVES: There are 3 objectives of this review. To (1) review case reports of SS associated with the combination of tramadol and antidepressant drugs in recommended doses, (2) describe the mechanisms of the drug interaction, and (3) identify the potential risk factors for SS.
METHODS: Case reports of SS associated with tramadol and antidepressants were identified via Cochrane Library, PubMed, and Ovid (through October 2012) using search terms SS, tramadol, antidepressants, fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, escitalopram, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, milnacipran, trazodone, vilazodone, and bupropion. Cases involving monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants were excluded.
RESULTS: Nine articles were identified describing 10 cases of suspected SS associated with therapeutic doses of tramadol combined with an antidepressant. Mechanisms of the drug-drug interactions involve pharmacodynamic, pharmacokinetic, and possible pharmacogenetic factors.
CONCLUSIONS: Review of the available case reports of tramadol combined with antidepressant drugs in therapeutic doses indicates caution in regard to the potential for SS but does not constitute a contraindication to their use. Tramadol is only contraindicated in combination with MAOIs but not other antidepressants in common use today. These case reports do suggest several factors associated with a greater risk of SS, including increased age, higher dosages, and use of concomitant potent cytochrome P450 2D6 inhibitors. Tramadol can be safely combined with antidepressants; however, monitoring and counseling patients are prudent when starting a new serotonergic agent or when doses are increased.

Entities:  

Keywords:  antidepressants; drug–drug interactions; serotonergic; serotonin syndrome; tramadol

Mesh:

Substances:

Year:  2013        PMID: 24153222     DOI: 10.1177/0897190013504957

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  11 in total

Review 1.  Duloxetine for the reduction of opioid use in elective orthopedic surgery: a systematic review and meta-analysis.

Authors:  Mark W Branton; Thomas J Hopkins; Eric C Nemec
Journal:  Int J Clin Pharm       Date:  2021-01-18

Review 2.  Symptom burden in heart failure: assessment, impact on outcomes, and management.

Authors:  Craig M Alpert; Michael A Smith; Scott L Hummel; Ellen K Hummel
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

3.  Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining Analysis from the Patients' Perspective.

Authors:  John A Bumpus
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-29

4.  Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.

Authors:  John A Zebala; Shawn L Searle; Lynn R Webster; Matt S Johnson; Aaron D Schuler; Dean Y Maeda; Stuart J Kahn
Journal:  J Pain       Date:  2019-04-18       Impact factor: 5.820

5.  Centrally administered CYP2D inhibitors increase oral tramadol analgesia in rats.

Authors:  Douglas M McMillan; Ahmed A El-Sherbeni; Janielle Richards; Rachel F Tyndale
Journal:  Brain Res Bull       Date:  2020-09-11       Impact factor: 4.077

6.  The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord injury: 2021 update.

Authors:  Eldon Loh; Magdalena Mirkowski; Alexandria Roa Agudelo; David J Allison; Brooke Benton; Thomas N Bryce; Sara Guilcher; Tara Jeji; Anna Kras-Dupuis; Denise Kreutzwiser; Oda Lanizi; Gary Lee-Tai-Fuy; James W Middleton; Dwight E Moulin; Colleen O'Connell; Steve Orenczuk; Patrick Potter; Christine Short; Robert Teasell; Andrea Townson; Eva Widerström-Noga; Dalton L Wolfe; Nancy Xia; Swati Mehta
Journal:  Spinal Cord       Date:  2022-02-05       Impact factor: 2.473

Review 7.  Safety issues of current analgesics: an update.

Authors:  Irina Cazacu; Cristina Mogosan; Felicia Loghin
Journal:  Clujul Med       Date:  2015-04-15

8.  Dependence potential of tramadol: behavioral pharmacology in rodents.

Authors:  Hye Jin Cha; Min Ji Song; Kwang-Wook Lee; Eun Jung Kim; Young-Hoon Kim; Yunje Lee; Won-Keun Seong; Sa-Ik Hong; Choon-Gon Jang; Han Sang Yoo; Ho-Sang Jeong
Journal:  Biomol Ther (Seoul)       Date:  2014-11-30       Impact factor: 4.634

9.  Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.

Authors:  Marzia Lazzari; Claudio Marcassa; Silvia Natoli; Roberta Carpenedo; Clarissa Caldarulo; Maria B Silvi; Mario Dauri
Journal:  Clin Interv Aging       Date:  2016-05-13       Impact factor: 4.458

10.  Tramadol-Induced Mood Elevation in a Patient with No Previous Psychiatric History.

Authors:  Mugtaba Osman; Mashael Mustafa
Journal:  Case Rep Psychiatry       Date:  2018-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.